AmacaThera Partners with Global Pharma to Develop Long-Acting Biologic Using AmacaGel™

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced a new pipeline program in collaboration with a leading global pharmaceutical company. Through this partnership, a single-injection, long-acting biologic will be developed using AmacaThera's advanced hydrogel delivery platform, AmacaGel™, in combination with the partner's therapeutic. Co-funded by both organizations, the initiative will leverage their complementary strengths and resources to accelerate the development of this innovative biologic.

AmacaThera is an OBIO® member, an alumnus of all OBIO® programs, and presented at the OBIO® Investment Summit.

Read more
Arsheen Kaur
Previous

Canada Should Invest in Itself Instead of Subsidizing Foreign Biotechnology Companies
Next

Spiderwort Biotechnologies Announces State-of-the-Art ISO 5 Cleanroom Facility